Gregory holds Ph.D in organic chemistry from the University of California, Los Angeles and did his postdoctoral work in organic synthesis at Stanford University. He has over 20 years of experience in the area of chemistry and has held key positions at various global organisations including Astra Zeneca and Bristol-Myers Squibb. At BMS Greg led projects in the development of the anti-hepatitis B virus nucleoside analog entacavir, launched in 2004 under the trade name Baraclude. He has authored or co-authored more than 40 peer-reviewed chemistry and medicinal chemistry journal articles and book chapters, and is inventor on 37 patents. Prior to joining Syngene in 2015, Greg worked with Astrazeneca as Associate Director.